secwatch.observer — SEC 8-K summary
======================================

Issuer:     Enveric Biosciences, Inc. (ENVB)
CIK:        0000890821
Form:       8-K
Filed at:   2024-11-12T23:59:59+00:00
Accession:  0001493152-24-044572
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Enveric out-licenses EB-002 to MycoMedica for up to $62M milestones plus royalties
--------------------------------------------------------------------------------

- Exclusive global license for EB-002 (EVM201) to treat neuropsychiatric disorders.
- Enveric receives modest upfront payments; eligible for up to $62M in development/sales milestones.
- Tiered single-digit royalties on all future sales; MycoMedica has buyout options.
- Enveric will focus resources on lead candidate EB-003, targeting IND filing in 2025.
- MycoMedica assumes all future preclinical, clinical, and commercial development costs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/890821/000149315224044572/0001493152-24-044572-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/890821/000149315224044572/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-044572

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer